This study shows that bariatric surgery is more effective than GLP‐1 receptor agonists in reducing the risk of NASH, liver cirrhosis and hepatocellular carcinoma in obese patients. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.